IMGN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 116468 min ago

@ $31.23

Išleistas: 8 vas. 2024 @ 16:30

Grąža: 0.02%

Ankstesnis signalas: vas. 7 - 22:55

Ankstesnis signalas: Pirkimas

Grąža: 5.67 %

Live Chart Being Loaded With Signals

Commentary (9 vas. 2024 @ 22:58):

Stats
Šios dienos apimtis	19.31M
Vidutinė apimtis	8.29M
Rinkos kapitalizacija	8.73B
EPS	$0 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-111.55
ATR14	$0.306 (0.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mitchell Dean J	Sell	103 000	Common Stock
2024-02-12	Mitchell Dean J	Sell	13 090	Restricted Stock Unit
2024-02-12	Mitchell Dean J	Sell	142 667	Deferred Share Unit
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 8 781 240

Tūris Koreliacija

Ilgas: 0.24 (neutral)

Trumpas: 0.25 (neutral)

Signal:(82.516) Neutral

ImmunoGen Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
HOL	0.945
IRBT	0.93
SLNG	0.929
RTPY	0.927
KBSF	0.926
LGMK	0.92
RPID	0.919
FIBK	0.917
GBCI	0.917
LYEL	0.917

10 Labiausiai neigiamai susiję koreliacijos
AEAE	-0.941
ENTF	-0.941
CCTS	-0.941
HORI	-0.939
GHIX	-0.938
FIAC	-0.938
XPAX	-0.938
NECB	-0.936
ADAL	-0.935
ACAB	-0.935

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ImmunoGen Inc Koreliacija - Valiuta/Žaliavos

-0.22
( neutral )

0.51
( weak )

0.55
( weak )

-0.04
( neutral )

-0.02
( neutral )

0.26
( neutral )

ImmunoGen Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$108.78M
Bruto pelnas:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
Pajamos:	$108.78M
Bruto pelnas:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
Pajamos:	$108.78M
Bruto pelnas:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2020
Pajamos:	$132.30M
Bruto pelnas:	$17.71M (13.38 %)
EPS:	$-0.250

Financial Reports:

No articles found.

ImmunoGen Inc

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.